作为肝癌患者的预后生物标志物的表达。
Expression as a Prognostic Biomarker for Liver Cancer Patients.
机构信息
Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, China.
Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin 130021, China.
出版信息
Dis Markers. 2019 Oct 17;2019:9037131. doi: 10.1155/2019/9037131. eCollection 2019.
BACKGROUND AND OBJECTIVE
Liver cancer is a highly malignant tumor, and patients typically have poor prognoses. Metabolic reprogramming is a hallmark of cancer, and downregulation of oxoglutarate dehydrogenase-like (OGDHL) contributes to the onset and progression of several cancers. We examined the role of altered expression in liver cancer and determined its value as a diagnostic and prognostic indicator for patients.
MATERIAL AND METHODS
R (version 3.5.1) and several R extensions were used for data mining of The Cancer Genome Atlas (TCGA) dataset (including RNAseq and clinical information) and statistical analysis. Receiver operating characteristic analysis was used to determine the diagnostic value of . The chi-squared test was used to identify the clinical correlates of downregulation. Survival analysis (with the log-rank test) and univariate and multivariate Cox analysis were used to evaluate the effect of expression on overall survival (OS) and relapse-free survival. TCGA was used for analysis of gene set enrichment.
RESULTS
had lower expression in cancerous liver tissues than noncancerous adjacent tissues, and low expression correlated with more advanced patient age, histologic grade, stage, T classification, and poor survival. Patients with lower expression had shorter OS and relapse-free survival. Multivariate Cox regression indicated that low expression was an independent risk factor for poor prognosis. Gene set enrichment analysis indicated enrichment of the mitotic spindle, G2M checkpoint, and E2F targets in the low expression phenotype.
CONCLUSION
has potential as a diagnostic and prognostic biomarker for liver cancer.
背景与目的
肝癌是一种高度恶性的肿瘤，患者的预后通常较差。代谢重编程是癌症的一个标志，而氧化戊二酸脱氢酶样（OGDHL）的下调导致了多种癌症的发生和发展。我们研究了在肝癌中表达改变的作用，并确定其作为患者诊断和预后指标的价值。
材料与方法
使用 R（版本 3.5.1）和几个 R 扩展程序对癌症基因组图谱（TCGA）数据集（包括 RNAseq 和临床信息）进行数据挖掘和统计分析。采用受试者工作特征分析（ROC）确定 的诊断价值。采用卡方检验确定 的下调与临床相关的因素。采用生存分析（对数秩检验）以及单因素和多因素 Cox 分析评估 表达对总生存期（OS）和无复发生存期（RFS）的影响。使用 TCGA 进行基因集富集分析。
结果
在肝癌组织中的表达低于癌旁正常组织，低表达与患者年龄较大、组织学分级较高、分期较晚、T 分类较差和生存较差相关。 表达水平较低的患者 OS 和 RFS 较短。多因素 Cox 回归分析表明，低表达是预后不良的独立危险因素。基因集富集分析表明，低 表达表型中存在有丝分裂纺锤体、G2M 检查点和 E2F 靶基因的富集。
结论
可能是肝癌的一种有潜力的诊断和预后生物标志物。
Zotero 插件